ActoGeniX reports positive results from Phase I trial of AG014 to treat inflammatory bowel disease
The results show that AG014 is safe and well tolerated while providing localized gastro-intestinal (GI) exposure. AG014 is the company’s ActoBiotics delivery platform and works by expressing and